Access the full text.
Sign up today, get DeepDyve free for 14 days.
J. Staessen, Ji-Guang Wang, L. Thijs (2003)
Cardiovascular prevention and blood pressure reduction: a quantitative overview updated until 1 March 2003Journal of Hypertension, 21
R. Fogari, A. Mugellini, A. Zoppi, L. Corradi, P. Preti, P. Lazzari, G. Derosa (2002)
Losartan and perindopril effects on plasma plasminogen activator inhibitor-1 and fibrinogen in hypertensive type 2 diabetic patients.American journal of hypertension, 15 4 Pt 1
A. Chobanian, G. Bakris, H. Black, W. Cushman, L. Green, J. Izzo, Daniel Jones, B. Materson, S. Oparil, J. Wright, E. Roccella (2003)
Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure.Hypertension, 42 6
(1993)
Increased risk of cardiovascular complications in hypertensive type 2 diabetic patientsJ Hypertens, 11
M. Stearne, S. Palmer, M. Hammersley, S. Franklin, R. Spivey, J. Levy, C. Tidy, N. Bell, J. Steemson, B. Barrow, R. Coster, K. Waring, J. Nolan, E. Truscott, N. Walravens, L. Cook, H. Lampard, C. Merle, P. Parker, J. Mcvittie, I. Draisey, L. Murchison, A. Brunt, M. Williams, D. Pearson, X. Petrie, M. Lean, D. Walmsley, M. Lyall, E. Christie, J. Church, E. Thomson, A. Farrow, J. Stowers, M. Stowers, K. McHardy, N. Patterson, A. Wright, N. Levi, A. Shearer, R. Thompson, G. Taylor, S. Rayton, M. Bradbury, A. Glover, A. Smyth-Osbourne, C. Parkes, J. Graham, P. England, S. Gyde, C. Eagle, B. Chakrabarti, J. Smith, J. Sherwell, E. Kohner, A. Dornhurst, M. Doddridge, M. Dumskyj, S. Walji, P. Sharp, M. Sleightholm, G. Vanterpool, C. Rose, G. Frost, M. Roseblade, S. Elliott, S. Forrester, M. Foster, K. Myers, R. Chapman, J. Hayes, R. Henry, M. Featherston, G. Archbold, M. Copeland, R. Harper, I. Richardson, S. Martín, H. Davison, D. Hadden, L. Kennedy, A. Atkinson, A. Culbert, C. Hegan, H. Tennet, N. Webb, I. Robinson, J. Holmes, P. Bell, D. McCance, J. Rutherford, S. Nesbitt, A. Spathis, S. Hyer, M. Nanson, L. James, J. Tyrell, C. Davis, P. Strugnell, M. Booth, H. Petrie, D. Clark, B. Rice, S. Hulland, J. Barron, J. Yudkin, B. Gould, J. Singer, A. Badenock, M. Eckert, K. Alibhai, E. Marriot, C. Cox, R. Price, M. Fernandez, A. Ryle, S. Clarke, G. Wallace, E. Mehmed, S. Macfarlane, R. Greenwood, J. Wilson, M. Denholm, R. Temple, K. Whitfield, F. Johnson, C. Munroe, S. Gorick, E. Duckworth, M. Flatman, S. Rainbow, L. Borthwick, D. Wheatcroft, R. Seaman, R. Christie, W. Wheatcroft, P. Musk, J. White, S. McDougal, M. Bond, P. Raniga, R. Newton, R. Jung, C. Roxburgh, B. Kilgallon, L. Dick, N. Waugh, S. Kilby, A. Ellingford, J. Burns, C. Fox, M. Holloway, H. Coghill, N. Hein, A. Fox, W. Cowan, M. Richard, K. Quested, S. Evans, R. Paisey, N. Brown, A. Tucker, R. Paisey, F. Garrett, J. Hogg, P. Park, K. Williams, Philip Harvey, R. Wilcocks, S. Mason, J. Frost, C. Warren, P. Rocket, L. Bower, J. Roland, D. Brown, J. Youens, K. Stanton-King, H. Mungall, W. Maddison, D. Donnelly, S. King, P. Griffin, S. Smith, S. Church, G. Dunn, Apr Wilson, K. Palmer, P. Brown, D. Humphriss, A. Davidson, R. Rose, L. Armistead, S. Townsend, P. Poon, I. Peacock, N. Culverwell, M. Charlton, B. Connolly, J. Peacock, J. Barrett, J. Wain, W. Beeston, G. King, P. Hill, A. Boulton, A. Robertson, Katoulis, A. Olukoga, H. McDonald, S. Kumar, F. Abouaesha, B. Abuaisha, E. Knowles, S. Higgins, J. Booker, J. Sunter, K. Breislin, R. Parker, P. Raval, J. Curwell, H. Davenport, G. Shawcross, A. Prest, J. Grey, H. Cole, C. Sereviratne, R. Young, T. Dornan, J. Clyne, M. Gibson, I. O'Connell, L. Wong, S. Wilson, K. Wright, C. Wallace, D. McDowell, A. Burden, E. Sellén, R. Gregory, M. Roshan, N. Vaghela, M. Burden, C. Sherriff, J. Clarke, J. Grenfell, J. Tooke, K. Macleod, C. Searnark, M. Rammell, C. Pym, J. Stockman, C. Yeo, J. Piper, L. Leighton, E. Green, M. Hoyle, K. Jones, A. Hudson, A. James, A. Shore, A. Higham, B. Martin (1998)
Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38BMJ, 317
M. Ezzati, A.D. Lopez, A. Rodgers (2002)
Selected major risk factors and global and regional burden of diseaseLancet, 360
G. Bakris, M. Weir, Shahnaz Shanifar, Zhongxin Zhang, J. Douglas, D. Dijk, B. Brenner (2003)
Effects of blood pressure level on progression of diabetic nephropathy: results from the RENAAL study.Archives of internal medicine, 163 13
M. Pohl, S. Blumenthal, D. Cordonnier, F. Álvaro, G. Deferrari, G. Eisner, E. Esmatjes, R. Gilbert, L. Hunsicker, J. Faria, R. Mangili, Jack Moore, E. Reisin, E. Ritz, G. Schernthaner, S. Spitalewitz, H. Tindall, R. Rodby, E. Lewis (2005)
Independent and additive impact of blood pressure control and angiotensin II receptor blockade on renal outcomes in the irbesartan diabetic nephropathy trial: clinical implications and limitations.Journal of the American Society of Nephrology : JASN, 16 10
K. Berthet, B. Neal, J. Chalmers, S. MacMahon, M. Bousser, S. Colman, M. Woodward (2004)
Reductions in the risks of recurrent stroke in patients with and without diabetes: The PROGRESS TrialBlood Pressure, 13
Mayank Patel, A. Bhalla (2008)
Images in clinical medicine. Paget's disease of the mandible.The New England journal of medicine, 358 6
Louis Monnier, Pham Tc, L. Aguirre, A. Orsetti, J. Mirouze (1978)
Influence of Indigestible Fibers on Glucose ToleranceDiabetes Care, 1
R. Schrier, R. Estacio, A. Esler, P. Mehler (2002)
Effects of aggressive blood pressure control in normotensive type 2 diabetic patients on albuminuria, retinopathy and strokes.Kidney international, 61 3
G. Mancia, G. Backer, A. Dominiczak, R. Cífková, R. Fagard, G. Germano, G. Grassi, A. Heagerty, S. Kjeldsen, S. Laurent, K. Narkiewicz, L. Ruilope, A. Rynkiewicz, R. Schmieder, H. Boudier, A. Zanchetti (2007)
2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC)Journal of Hypertension, 25
F. Turnbull, B. Neal, C. Algert, J. Chalmers, N. Chapman, J. Cutler, M. Woodward, S. MacMahon (2005)
Effects of different blood pressure-lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus: results of prospectively designed overviews of randomized trials.Archives of internal medicine, 165 12
B. Galan, V. Perkovic, T. Ninomiya, Avinesh Pillai, Anushka Patel, A. Cass, B. Neal, N. Poulter, S. Harrap, C. Mogensen, M. Cooper, M. Marre, B. Williams, P. Hamet, G. Mancia, M. Woodward, P. Glasziou, D. Grobbee, S. MacMahon, J. Chalmers (2009)
Lowering blood pressure reduces renal events in type 2 diabetes.Journal of the American Society of Nephrology : JASN, 20 4
A. Patel, S. MacMahon, J. Chalmers (2007)
Effects of fixed combination of perindopril and indapamide on microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controllled trialLancet, 370
J. Staessen, Ji-Guang Wang, L. Thijs (2003)
What can be expected from optimal blood pressure control?Journal of hypertension. Supplement : official journal of the International Society of Hypertension, 21 2
J. Buse, H. Ginsberg, G. Bakris, N. Clark, F. Costa, R. Eckel, V. Fonseca, H. Gerstein, S. Grundy, R. Nesto, M. Pignone, J. Plutzky, D. Porte, R. Redberg, Kimberly Stitzel, N. Stone (2006)
Primary Prevention of Cardiovascular Diseases in People With Diabetes MellitusDiabetes Care, 30
T. Berl, L. Hunsicker, J. Lewis, M. Pfeffer, J. Porush, J. Rouleau, P. Drury, E. Esmatjes, D. Hricik, M. Pohl, I. Raz, P. Vanhille, T. Wiegmann, B. Wolfe, F. Locatelli, S. Goldhaber, E. Lewis (2005)
Impact of achieved blood pressure on cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial.Journal of the American Society of Nephrology : JASN, 16 7
S. Wild, G. Roglić, A. Green, R. Sicree, H. King (2004)
Global prevalence of diabetes: estimates for the year 2000 and projections for 2030.Diabetes care, 27 5
R. Estacio, B. Jeffers, Nancy Gifford, R. Schrier (2000)
Effect of blood pressure control on diabetic microvascular complications in patients with hypertension and type 2 diabetes.Diabetes care, 23 Suppl 2
A. Zanchetti, L. Hansson, D. Clement, D. Elmfeldt, S. Julius, T. Rosenthal, B. Waeber, H. Wedel (2003)
Benefits and risks of more intensive blood pressure lowering in hypertensive patients of the HOT study with different risk profiles: does a J-shaped curve exist in smokers?Journal of Hypertension, 21
B. Brenner, M. Cooper, D. Zeeuw, W. Keane, W. Mitch, H. Parving, G. Remuzzi, S. Snapinn, Zhonxin Zhang, S. Shahinfar (2001)
Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy.The New England journal of medicine, 345 12
S. Laurent (2005)
Evidence for benefits of perindopril in hypertension and its complications.American journal of hypertension, 18 9 Pt 2
J. Stamler, O. Vaccaro, J. Neaton, D. Wentworth (1993)
Diabetes, Other Risk Factors, and 12-Yr Cardiovascular Mortality for Men Screened in the Multiple Risk Factor Intervention TrialDiabetes Care, 16
L. Hansson, A. Zanchetti, S. Carruthers, B. Dahlöf, D. Elmfeldt, S. Julius, J. Ménard, K. Rahn, H. Wedel, S. Westerling (1998)
Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trialThe Lancet, 351
S. Lewington, R. Clarke, N. Qizilbash, R. Peto, R. Collins (2002)
Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studiesThe Lancet, 360
J. Mann, H. Gerstein, S. Yusuf (2000)
Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators.The Lancet
(1993)
Prevalence of hypertension in newly presenting type 2 diabetic patients and the association with risk factors for cardiovascular and diabetic complicationsJ Hypertens, 11
T. Perneger, F. Brancati, P. Whelton, M. Klag (1994)
End-Stage Renal Disease Attributable to Diabetes MellitusAnnals of Internal Medicine, 121
D. Aronson (2003)
Cross-linking of glycated collagen in the pathogenesis of arterial and myocardial stiffening of aging and diabetesJournal of Hypertension, 21
D. Giugliano, R. Marfella, R. Acampora, R. Giunta, L. Coppola, F. D'onofrio (1998)
Effects of Perindopril and Carvedilol on Endothelium-Dependent Vascular Functions in Patients With Diabetes and HypertensionDiabetes Care, 21
L. Tarnow, P. Rossing, M. Gall, F. Nielsen, H. Parving (1994)
Prevalence of Arterial Hypertension in Diabetic Patients Before and After the JNC-VDiabetes Care, 17
Anushka Patel (2007)
Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trialThe Lancet, 370
Sheng Kang, Y. Wu, N. An, MingBao Ren (2004)
A systematic review and meta-analysis of the efficacy and safety of a fixed, low-dose perindopril-indapamide combination as first-line treatment of hypertension.Clinical therapeutics, 26 2
R. Turner, R. Holman, D. Matthews, P. Bassett, R. Coster, I. Stratton, C. Cull, R. Peto, V. Frighi, I. Kennedy, S. Manley, E. Bown, E. Eeley, I. Ross, T. Dornan, A. Wright, Neil Haw., E. Kohner, Stephen Aldington, N. Keen, C. Rose, A. Fletcher, C. Battersby, J. Yudkin, S. Oakes, M. Stearn, S. Palmer, M. Hammersley, S. Franklin, R. Spivey, Hockaday Tdr., L. Murchison, Brunt Ahe., M. Williams, D. Macpearson, Petrie Xmp., Lean Mej., N. Levi, Shearer Aci., Thompson Rjw., M. Doddridge, Hayes, R. Henry, M. Fetherston, Hadden, L. Kennedy, A. Atkinson, A. Culbert, C. Hagan, A. Spathis, M. Nanson, L. James, J. Tyrell, C. Gould, J. Singer, M. Badenoch, R. Greenwood, J. Wilson, M. Denholm, R. Temple, L. Borthwick, D. Wheatcroft, R. Seaman, R. Christie, R. Newton, R. Jung, C. Roxburgh, B. Kilgallan, C. Fox, M. Holloway, H. Coghill, R. Paisey, Brown Npr., A. Tucker, J. Roland, D. Brown, J. Youens, P. Brown, Davidson Ajm., Peacock Ida., Culverwell Njc., M. Charlton, Connolly Bps., Boulton Ajm., A. Robertson, R. Young, Clyne, A. Burden, E. Sellén, J. Tooke (1993)
Hypertension in Diabetes Study (HDS): I. Prevalence of hypertension in newly presenting type 2 diabetic patients and the association with risk factors for cardiovascular and diabetic complications.Journal of hypertension, 11 3
For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group
E. Lewis, L. Hunsicker, W. Clarke, T. Berl, M. Pohl, J. Lewis, E. Ritz, R. Atkins, R. Rohde, I. Raz (2001)
Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes.The New England journal of medicine, 345 12
R. Turner, R. Holman (1998)
Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group.BMJ
E. Lewis, L. Hunsicker, R. Bain, R. Rohde (1993)
The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group.The New England journal of medicine, 329 20
Anushka Patel, S. MacMahon, J. Chalmers, B. Neal, L. Billot, M. Woodward, M. Marre, M. Cooper, P. Glasziou, D. Grobbee, P. Hamet, S. Harrap, S. Heller, Li-sheng Liu, G. Mancia, C. Mogensen, C. Pan, N. Poulter, A. Rodgers, B. Williams, Severine Bompoint, B. Galan, R. Joshi, F. Travert (2008)
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.The New England journal of medicine, 358 24
H. Parving, Hendrik Lehnert, J. Bröchner-Mortensen, R. Gomis, S. Andersen, P. Arner (2001)
The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes.The New England journal of medicine, 345 12
C. Murray, Alan Lopez (1996)
Evidence-Based Health Policy--Lessons from the Global Burden of Disease StudyScience, 274
P. Kearney, Megan Whelton, K. Reynolds, P. Muntner, P. Whelton, Jiang He (2005)
Global burden of hypertension: analysis of worldwide dataThe Lancet, 365
M. Marre, J. Puig, F. Kokot, Margarita Fernández, G. Jermendy, L. Opie, V. Moyseev, A. Scheen, C. Ionescu-Tîrgoviste, M. Saldanha, A. Halabe, B. Williams, D. Mion, M. Ruiz, K. Hermansen, J. Tuomilehto, B. Finizola, Y. Gallois, P. Amouyel, J. Ollivier, R. Asmar (2004)
Equivalence of indapamide SR and enalapril on microalbuminuria reduction in hypertensive patients with type 2 diabetes: The NESTOR* studyJournal of Hypertension, 22
E. Lewis, L. Hunsicker, R. Bain, R. Rohde (1993)
The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy.The New England Journal of Medicine, 330
A. Tropeano, P. Boutouyrie, B. Pannier, R. Joannidés, E. Balkestein, S. Katsahian, B. Laloux, C. Thuillez, H. Struijker-Boudier, S. Laurent (2006)
Brachial Pressure–Independent Reduction in Carotid Stiffness After Long-Term Angiotensin-Converting Enzyme Inhibition in Diabetic HypertensivesHypertension, 48
D.M. Robinson, K. Wellington (2006)
Indapamide sustained release: a review of its use in the treatment of hypertensionDrugs, 66
M. Alderman, H. Cohen, S. Madhavan (1999)
Diabetes and cardiovascular events in hypertensive patients.Hypertension, 33 5
D. Campbell, F. Brackman (1990)
Cardiovascular protective properties of indapamide.The American journal of cardiology, 65 17
H. Parving, Andersen Ar, U. Smidt, E. Hommel, E. Mathiesen, Svendsen Pa (1987)
Effect of antihypertensive treatment on kidney function in diabetic nephropathy.British Medical Journal (Clinical research ed.), 294
S. Kuo, Pei-Dee, Y. Hung, An‐Tsz Hsieh, Ling-Yi Wu, C. Hsieh, Chih-Tsueng He, Tsao-Chin Yang, W. Lian (2003)
Effect of indapamide SR in the treatment of hypertensive patients with type 2 diabetes.American journal of hypertension, 16 8
P. Carey, D. Sheridan, A. Cordoue, D. Guez (1996)
Effect of indapamide on left ventricular hypertrophy in hypertension: a meta-analysis.The American journal of cardiology, 77 6
J.B. Buse, H.N. Ginsberg, G.L. Bakris (2007)
Primary prevention of cardiovascular diseases in people with diabetes mellitus: a scientific statement from the American Heart Association and the American Diabetes AssociationDiabetes Care, 30
D. Johnston (2001)
Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attackThe Lancet, 358
C. Mogensen, G. Viberti, S. Halimi, E. Ritz, L. Ruilope, G. Jermendy, J. Widimský, P. Sareli, J. Tatoň, J. Rull, G. Erdogan, P. Leeuw, A. Ribeiro, R. Sanchez, R. Mechmeche, J. Nolan, J. Sirotiaková, A. Hamani, A. Scheen, B. Hess, A. Luger, Stephen Thomas (2003)
Effect of Low-Dose Perindopril/Indapamide on Albuminuria in Diabetes: Preterax in Albuminuria Regression: PREMIERHypertension: Journal of the American Heart Association, 41
M. Burnier, A. Zanchi (2006)
Blockade of the renin–angiotensin–aldosterone system: a key therapeutic strategy to reduce renal and cardiovascular events in patients with diabetesJournal of Hypertension, 24
E. Standl, G. Berghe (2007)
Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary
P. Gosse (2006)
Perindopril/indapamide combination in the first-line treatment of hypertension and end-organ protectionExpert Review of Cardiovascular Therapy, 4
P. Conlin, W. Gerth, James Fox, J. Roehm, S. Boccuzzi (2001)
Four-Year persistence patterns among patients initiating therapy with the angiotensin II receptor antagonist losartan versus other artihypertensive drug classes.Clinical therapeutics, 23 12
C. Sweet (1990)
Issues surrounding a local cardiac renin system and the beneficial actions of angiotensin-converting enzyme inhibitors in ischemic myocardium.The American journal of cardiology, 65 19
A. Adler, I. Stratton, A. Neil, J. Yudkin, D. Matthews, C. Cull, A. Wright, R. Turner, R. Holman (2000)
Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational studyBMJ : British Medical Journal, 321
Hope Investigators, B. Wolffenbuttel (2000)
Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudyThe Lancet, 355
P. Svensson, U. Faire, P. Sleight, S. Yusuf, J. Östergren (2001)
Comparative Effects of Ramipril on Ambulatory and Office Blood Pressures: A HOPE SubstudyHypertension: Journal of the American Heart Association, 38
P. Ruggenenti, A. Fassi, Anelja Ilieva, Simona Bruno, I. Iliev, Varusca Brusegan, N. Rubis, Giulia Gherardi, Federica Arnoldi, M. Ganeva, B. Ene-Iordache, F. Gaspari, A. Perna, A. Bossi, R. Trevisan, A. Dodesini, G. Remuzzi (2004)
Preventing microalbuminuria in type 2 diabetes.The New England journal of medicine, 351 19
R. Ferrari, G. Pasanisi, P. Notarstefano, G. Campo, E. Gardini, C. Ceconi (2005)
Specific properties and effect of perindopril in controlling the renin-angiotensin system.American journal of hypertension, 18 9 Pt 2
Patients with type 2 diabetes mellitus exhibit a marked increase in cardiovascular and renal risk. A number of interventional trials have shown that these patients benefit greatly from aggressive BP lowering, especially when the drug regimen comprises an inhibitor of the renin-angiotensin system. The results of the placebo-controlled ADVANCE (Action in Diabetes and Vascular disease: PreterAx and DiamicroN MR Controlled Evaluation) trial, conducted in patients with type 2 diabetes, are exemplary in this respect. The systematic use of a fixed-dose combination containing the ACE inhibitor perindopril and the diuretic indapamide afforded substantial protection against cardiovascular mortality and myocardial infarction, while providing important renoprotection, reducing the development of micro- and macroalbuminuria, and allowing regression of nephropathy. The beneficial effects were obtained regardless of baseline BP and whether or not the patients were receiving antihypertensive therapy.
American Journal of Cardiovascular Drugs – Springer Journals
Published: Aug 17, 2012
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.